ClassID:

20306

A61K31/39 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring

Recent Application in this class:
#1
20260085036
2026-03-26

NOVEL NOOTROPIC PRODRUGS OF HENETHYLAMINE

#2
20250248969
2025-08-07

COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE

#3
20250197416
2025-06-19

PARTHENOLIDE DERIVATIVES AND USE THEREOF

#4
20250154180
2025-05-15

CRK-LIKE (CRKL) ADAPTOR PROTEIN INHIBITORS AND METHODS OF MAKING AND USING THE SAME

#5
20240350552
2024-10-24

THERAPEUTIC COMPOSITION CONTAINING CORNEAL ENDOTHELIUM REPLACEMENT CELLS

#6
20240317704
2024-09-26

PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE

#7
20240285578
2024-08-29

Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use

#8
20240197679
2024-06-20

NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS

#9
20240131001
2024-04-25

PHARMACEUTICAL APPLICATION OF FUSED RING PHENOLIC COMPOUNDS

#10
20230321034
2023-10-12

Short-acting psychoactive compounds of the MDMA class

#11
20230285432
2023-09-14

Pharmaceutical composition, methods for treating and uses thereof

#12
20220313702
2022-10-06

OXATHIAZIN COMPOUNDS FOR INHIBITING GAPDH

#13
20210379060
2021-12-09

SPT5 INHIBITORS AND USES THEREOF

#14
20210346415
2021-11-11

PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF

#15
20210283100
2021-09-16

ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER

#16
20210230176
2021-07-29

Hepatitis B antiviral agents

#17
20200199143
2020-06-25

Hepatitis B antiviral agents

#18
20200085851
2020-03-19

PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF

#19
20190365768
2019-12-05

N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases

#20
20190153010
2019-05-23

Antibacterial sideromycins

#21
20190099384
2019-04-04

Methods for inhibiting conversion of choline to trimethylamine (TMA)

#22
20190084994
2019-03-21

Hepatitis B antiviral agents

#23
20190064161
2019-02-28

OLFR90 specificity and methods of detection

#24
20180230138
2018-08-16

Cathepsin K inhibitors and application thereof

#25
20180008569
2018-01-11

PROSTAGLANDIN TRANSPORTER INHIBITORS FOR INHIBITING OVULATION

#26
20170354639
2017-12-14

DITERPENOID DERIVATIVES AND METHODS OF USE THEREOF

#27
20170253609
2017-09-07

Hepatitis B antiviral agents

#28
20170196876
2017-07-13

Oxathiazine derivatives as antibacterial and anticancer agents

#29
20160159759
2016-06-09

Oxathiazine derivatives as antibacterial and anticancer agents

#30
20150313872
2015-11-05

Combination of a slow sodium current blocker and a sinus If current inhibitor, and the pharmaceutical compositions containing said combination

#31
20150266853
2015-09-24

Endoparasite control agent

#32
20150196546
2015-07-16

Inhibitors of CRL4 ubiquitin ligase and uses thereof

#33
20150182534
2015-07-02

Oxathiazine derivatives as antibacterial and anticancer agents

#34
20150051233
2015-02-19

Methods and compositions for treatment of fibrosis

#35
20140364389
2014-12-11

Combination Therapy

#36
20140235692
2014-08-21

Use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine for preventing and/or treating cardiotoxic effects caused by chemotherapy and/or radiation

#37
20140206743
2014-07-24

Use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine for treating cancer and in particular for preventing and/or treating cancer metastases

#38
20140179694
2014-06-26

Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia

#39
20140106003
2014-04-17

Thioxanthone-based autophagy inhibitor therapies to treat cancer

#40
20140038911
2014-02-06

Pharmaceutical composition, methods for treating and uses thereof

#41
20130078233
2013-03-28

COMPOSITIONS AND METHODS USING SAME FOR TREATING AMYLOID-ASSOCIATED DISEASES

#42
20130045253
2013-02-21

ORAL ANTIDEPRESSANT FORMULATION WITH REDUCED EXCIPIENT LOAD

#43
20120289577
2012-11-15

COMPOSITION FOR TREATING OR PREVENTING HEARING LOSS COMPRISING NAPHTHOQUINONE-BASED COMPOUNDS

#44
20120010259
2012-01-12

Methods of Treating an Overweight or Obese Subject

#45
20110275696
2011-11-10

Thioxanthone-based autophagy inhibitor therapies to treat cancer

#46
20110206769
2011-08-25

Oral antidepressant formulation with reduced excipient load

#47
20110104249
2011-05-05

Oncotherapeutic application of inhibitors of high-affinity glucose transporters

#48
20110046147
2011-02-24

17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES

#49
20110046076
2011-02-24

PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF

#50
20100297109
2010-11-25

METHODS FOR INHIBITING FASCIN

#51
20100041617
2010-02-18

Modulating mxa expression

#52
20100016208
2010-01-21

PHOTOACTIVATABLE ANTIMICROBIAL AGENTS

#53
20090306051
2009-12-10

Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders

#54
20090176805
2009-07-09

Derivatives of ethylene methanedisulfonate as cancer chemotherapeutic agents

#55
20090156471
2009-06-18

Use of anti-amyloid agents for treating and typing pathogen infections

#56
20090137567
2009-05-28

Methods for treating blood disorders

#57
20080275108
2008-11-06

VACUOLAR-TYPE (H+)-ATPase-INHIBITING COMPOUNDS, COMPOSITIONS, AND USES THEREOF

#58
20080075692
2008-03-27

METHODS FOR TREATING BLOOD DISORDERS

#59
20070066575
2007-03-22

Methods and compositions for mitigating pain

#60
20060234987
2006-10-19

Neuroprotective benzo 1 3 oxathiol 2 ones

#61
20060194777
2006-08-31

Compositions and methods using same for treating amyloid-associated diseases

#62
20060122264
2006-06-08

Stem cell invasion inhibitor

#63
20060035959
2006-02-16

Pharmaceutical formulations containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds

#64
20050288326
2005-12-29

Combination therapy

#65
20050245460
2005-11-03

Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders

#66
20050137191
2005-06-23

Nitrate esters and their use for mitigating cellular damage

#67
20050004107
2005-01-06

Telmisartan sodium salt pharmaceutical formulation